|Application ||WB, IHC|
|Calculated MW||45399 Da|
|Positive Control||Western blot: Jurkat, K562, NCI-H460 cell lysate, IHC: human hepatocarcinoma tissue.|
|Application & Usage||Western blot: ~1:1000, IHC: ~1:10-1:50.|
|Other Names||APOA4; Apolipoprotein A-IV; Apolipoprotein A4|
|Formulation||100 µl of antibody in PBS with 0.09% (W/V) sodium azide|
|Handling||The antibody solution should be gently mixed before use.|
|Reconstitution & Storage||-20 °C|
|Precautions||ApoA4 Antibody (NT) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||May have a role in chylomicrons and VLDL secretion and catabolism. Required for efficient activation of lipoprotein lipase by ApoC-II; potent activator of LCAT. Apoa-IV is a major component of HDL and chylomicrons.|
|Tissue Location||Synthesized primarily in the intestine and secreted in plasma|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Apolipoproteins are plasma lipoproteins that function as transporters of lipids and cholesterol in the circulatory system. Chylomicrons are a fundamental class of apolipoproteins containing very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL). Apolipoprotein A-IV (ApoA4) is a glycoprotein that exists as a free apolipoprotein in human plasma. ApoA4 activates the lecithin cholesterol acyl transferase to modulate the rate of lipid transfer protein (LTP) activity. Additional evidence suggests that ApoA4 may also act as an antioxidant to inhibit LDL oxidation in the atherosclerosis model.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.